Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer

Lixte Biotechnology Holdings Inc LIXT has announced that its lead compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer (SCLC).
Dr. Ravi Salgia is the paper's corresponding author. He is also the principal investigator for a recently opened Phase 1b trial for patients with previously untreated advanced small cell lung cancer, in which LB-100 is added to a standard regimen of carboplatin, etoposide, and atezolizumab.
The researchers found multiple metabolic changes associated with cell death in these cancer cells when exposed to LB-100 alone and combined with the drugs in this standard clinical regimen.
LB-100 increased the effectiveness of a number of anti-cancer drugs against several different types of human cancers without increasing toxicity in animal models.
Price Action: LIXT shares are up 25.8% at $3.52 during the market session on the last check Tuesday.